In the case of OBG, a phase I clinical trial has defined the maximum tolerated dose of a single dose of TMZ when combined with OBG and has determined the dose of OBG that depletes tumor MGMT activity for 48 h [39]. The gene discussed is MGMT; the disease is neoplasm.